Design, synthesis and antitumor activity of 5-trifluoromethylpyrimidine derivatives as EGFR inhibitors

References

• Chong CR, Janne PA. The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med. 2013;19(11):1389–400.
   PubMed Web of Science ®Google Scholar
• Ayati A, Moghimi S, Salarinejad S, et al. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem. 2020;99:103811.
   PubMed Web of Science ®Google Scholar
• Ohashi K, Maruvka YE, Michor F, Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol. 2013;31(8):1070–80.
   PubMed Web of Science ®Google Scholar
• Yewale C, Baradia D, Vhora I, et al. Epidermal growth factor receptor targeting in cancer: a review of trends and strategies. Biomaterials. 2013;34(34):8690–707.
   PubMed Web of Science ®Google Scholar
• Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B. 2015;5(5):390–401.
   PubMed Web of Science ®Google Scholar
• Chen X, Liang R, Zhu X. Anti-EGFR therapies in nasopharyngeal carcinoma. Biomed Pharmacother. 2020;131:110649.
   PubMed Web of Science ®Google Scholar
• Fischer T, Najjar A, Totzke F, et al. Discovery of novel dual inhibitors of receptor tyrosine kinases EGFR and PDGFR-β related to anticancer drug resistance. J Enzyme Inhib Med Chem. 2018;33(1):1–8.
   PubMed Web of Science ®Google Scholar
• Sos ML, Rode HB, Heynck S, et al. Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Res. 2010;70(3):868–74.
   PubMed Web of Science ®Google Scholar
• Hanan EJ, Eigenbrot C, Bryan MC, et al. Discovery of selective and noncovalent diaminopyrimidine-based inhibitors of epidermal growth factor receptor containing the T790M resistance mutation. J Med Chem. 2014;57(23):10176–91.
   PubMed Web of Science ®Google Scholar
• Le Y, Gan Y, Fu Y, et al. Design, synthesis and in vitro biological evaluation of quinazolinone derivatives as EGFR inhibitors for antitumor treatment. J Enzyme Inhib Med Chem. 2020;35(1):555–64.
   PubMed Web of Science ®Google Scholar
• Zhang T, Qu R, Chan S, et al. Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance. Mol Cancer. 2020;19(1):90–105.
   PubMed Web of Science ®Google Scholar
• Xiao Q, Qu R, Gao D, et al. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors. Bioorg Med Chem. 2016;24(12):2673–80.
   PubMed Web of Science ®Google Scholar
• Khattab RR, Alshamari AK, Hassan AA, et al. Click chemistry based synthesis, cytotoxic activity and molecular docking of novel triazole-thienopyrimidine hybrid glycosides targeting EGFR. J Enzyme Inhib Med Chem. 2021;36(1):504–16.
   PubMed Web of Science ®Google Scholar
• Othman IMM, Alamshany ZM, Tashkandi NY, et al. New pyrimidine and pyrazole-based compounds as potential EGFR inhibitors: synthesis, anticancer, antimicrobial evaluation and computational studies. Bioorg Chem. 2021;114:105078.
   PubMed Web of Science ®Google Scholar
• Abedinifar F, Babazadeh Rezaei E, Biglar M, et al. Recent strategies in the synthesis of thiophene derivatives: highlights from the 2012-2020 literature. Mol Divers. 2021;25(4):2571–604.
   PubMed Web of Science ®Google Scholar
• Pathania S, Chawla PA. Thiophene-based derivatives as anticancer agents: an overview on decade’s work. Bioorg Chem. 2020;101:104026.
   PubMed Web of Science ®Google Scholar
• Keri RS, Chand K, Budagumpi S, et al. An overview of benzo[b]thiophene-based medicinal chemistry. Eur J Med Chem. 2017;138:1002–33.
   PubMed Web of Science ®Google Scholar
• Zhang W, Fan Y-F, Cai C-Y, et al. Olmutinib (BI1482694/HM61713), a novel epidermal growth factor receptor tyrosine kinase inhibitor, reverses ABCG2-mediated multidrug resistance in cancer cells. Front Pharmacol. 2018;9:1097–110.
   PubMed Web of Science ®Google Scholar
• Mudududdla R, Guru SK, Wani A, et al. 3-(Benzo[d][1,3]dioxol-5-ylamino)-N-(4-fluorophenyl)thiophene-2-carboxamide overcomes cancer chemoresistance via inhibition of angiogenesis and P-glycoprotein efflux pump activity. Org Biomol Chem. 2015;13(14):4296–4309.
   PubMed Web of Science ®Google Scholar
• Dawood DH, Nossier ES, Abdelhameed MF, et al. Design, synthesis, anti-inflammatory evaluation and molecular docking of novel thiophen-2-ylmethylene-based derivatives as potential TNF-α production inhibitors. Bioorg Chem. 2022;122:105726.
   PubMed Web of Science ®Google Scholar
• Gomez-Monterrey I, Campiglia P, Aquino C, et al. Design, synthesis, and cytotoxic evaluation of acyl derivatives of 3-aminonaphtho[2,3-b]thiophene-4,9-dione, a quinone-based system. J Med Chem. 2011;54(12):4077–91.
   PubMed Web of Science ®Google Scholar
• Othman DIA, Selim KB, El-Sayed MA-A, et al. Design, synthesis and anticancer evaluation of new substituted thiophene-quinoline derivatives. Bioorg Med Chem. 2019;27(19):115026.
   PubMed Web of Science ®Google Scholar
• Saito Y, Taniguchi Y, Hirazawa S, et al. Effects of substituent pattern on the intracellular target of antiproliferative benzo[b]thiophenyl chromone derivatives. Eur J Med Chem. 2021;222:113578.
   PubMed Web of Science ®Google Scholar
• Yao T-T, Xie J-F, Liu X-G, et al. Integration of pharmacophore mapping and molecular docking in sequential virtual screening: towards the discovery of novel JAK2 inhibitors. RSC Adv. 2017;7(17):10353–60.
   Web of Science ®Google Scholar
• Liang Z, Ai J, Ding X, et al. Anthraquinone derivatives as potent inhibitors of c-Met kinase and the extracellular signaling pathway. ACS Med Chem Lett. 2013;4(4):408–13.
   PubMed Web of Science ®Google Scholar
• Gong L-L, Fang L-H, Peng J-H, et al. Integration of virtual screening with high-throughput screening for the identification of novel Rho-kinase I inhibitors. J Biotechnol. 2010;145(3):295–303.
   PubMed Web of Science ®Google Scholar
• Yan L, Wang Q, Liu L, Le Y. Design, synthesis and biological evaluation of a series of dianilinopyrimidines as EGFR inhibitors. J Enzyme Inhib Med Chem. 2022;37(1):832–43.
   PubMed Web of Science ®Google Scholar
• Wang L, Fang K, Cheng J, et al. Scaffold hopping of natural product evodiamine: discovery of a novel antitumor scaffold with excellent potency against colon cancer. J Med Chem. 2020;63(2):696–713.
   PubMed Web of Science ®Google Scholar
• Papakyriakou A, Katsarou ME, Belimezi M, et al. Discovery of potent vascular endothelial growth factor receptor-2 inhibitors. ChemMedChem. 2010;5(1):118–129.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Wang Q, Li L, et al. Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells. J Enzyme Inhib Med Chem. 2021;36(1):1205–16.
   PubMed Web of Science ®Google Scholar
• Astashkina A, Mann B, Grainger DW. A critical evaluation of in vitro cell culture models for high-throughput drug screening and toxicity. Pharmacol Ther. 2012;134(1):82–106.
   PubMed Web of Science ®Google Scholar
• Arkin MR, Tang Y, Wells JA. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem Biol. 2014;21(9):1102–14.
   PubMedGoogle Scholar
• Zhang S, Yan Z, Huang Y, et al. HelixADMET: a robust and endpoint extensible ADMET system incorporating self-supervised knowledge transfer. Bioinformatics. 2022;38(13):3444–53.
   PubMed Web of Science ®Google Scholar
• Guan L, Yang H, Cai Y, et al. ADMET-score - a comprehensive scoring function for evaluation of chemical drug-likeness. MedChemComm. 2019;10(1):148–57.
   PubMed Web of Science ®Google Scholar
• Barraza SJ, Denmark SE. Synthesis, reactivity, functionalization, and ADMET properties of silicon-containing nitrogen heterocycles. J Am Chem Soc. 2018;140(21):6668–84.
   PubMed Web of Science ®Google Scholar
• Wang J, Urban L, Bojanic D. Maximising use of in vitro ADMET tools to predict in vivo bioavailability and safety. Expert Opin Drug Metab Toxicol. 2007;3(5):641–65.
   PubMed Web of Science ®Google Scholar
• Xiong G, Wu Z, Yi J, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49:5–14.
   PubMed Web of Science ®Google Scholar
• Wang Z, Cherukupalli S, Xie M, et al. Contemporary medicinal chemistry strategies for the discovery and development of novel HIV-1 non-nucleoside reverse transcriptase inhibitors. J Med Chem. 2022;65(5):3729–3757.
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. Death and anti-death: tumour resistance to apoptosis. Nat Rev Cancer. 2002;2(4):277–88.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Li Y, Ni H-M, et al. Nrf2 but not autophagy inhibition is associated with the survival of wild-type epidermal growth factor receptor non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2016;310:140–9.
   PubMed Web of Science ®Google Scholar
• Kritikou I, Giannopoulou E, Koutras AK, et al. The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines. Pharm Biol. 2014;52(4):444–52.
   Web of Science ®Google Scholar
• Wang C, Xu S, Peng L, et al. Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. J Enzyme Inhib Med Chem. 2019;34(1):203–17.
   PubMed Web of Science ®Google Scholar
• Liang Y, Zhang T, Ren L, et al. Cucurbitacin IIb induces apoptosis and cell cycle arrest through regulating EGFR/MAPK pathway. Environ Toxicol Pharmacol. 2021;81:103542.
   PubMed Web of Science ®Google Scholar
• Lin TH, Lin GL. An anchor-dependent molecular docking process for docking small flexible molecules into rigid protein receptors. J Chem Inf Model. 2008;48(8):1638–55.
   PubMed Web of Science ®Google Scholar
• Caballero J. The latest automated docking technologies for novel drug discovery. Expert Opin Drug Discov. 2021;16(6):625–45.
   PubMed Web of Science ®Google Scholar
• Pinzi L, Rastelli G. Molecular docking: shifting paradigms in drug discovery. IJMS. 2019;20(18):4331–4351.
   Google Scholar
• Yan L, Li Y, Deng M, et al. Design, synthesis and biological activities of compounds containing 1,3,4-oxadiazole or 1,3,4-thiadiazole. Chin J Org Chem. 2020;40(3):731–9.
   Web of Science ®Google Scholar
• Ahmed EA, Mohamed MFA, Omran OA. Novel quinoxaline derivatives as dual EGFR and COX-2 inhibitors: synthesis, molecular docking and biological evaluation as potential anticancer and anti-inflammatory agents. RSC Adv. 2022;12(39):25204–16.
   PubMed Web of Science ®Google Scholar
• Stamos J, Sliwkowski MX, Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem. 2002;277(48):46265–72.
   PubMed Web of Science ®Google Scholar
• To C, Jang J, Chen T, et al. Single and dual targeting of mutant EGFR with an allosteric inhibitor. Cancer Discov. 2019;9(7):926–43.
   PubMed Web of Science ®Google Scholar